Suven Life Sciences secures product patents in Europe and Macau

For NCEs for treament of Neurodegenerative diseases

Suven Life Sciences announced the grant of one (1) product patent from Europe (2519514) and one (1) product patent from Macau (J/001808) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030 and 2029.

The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).

Powered by Capital Market - Live News